Skip to content
← Layoff Watch

Ultragenyx Pharmaceutical Inc.

About 1,000workers

SEC filingAnnounced

Ultragenyx Pharmaceutical Inc. tells investors it plans to cut about 1,000 positions

Industry
Biotech
Filed with the SEC
November 3, 2026
Whose workers
Scope not stated
In the report for
November 4, 2026

What happened

Ultragenyx Pharmaceutical Inc. told the SEC it plans to reduce its workforce by about 1,000 positions.

Sources

  • SEC EDGAR · SEC filing · Nov 3, 2026

    Savings actions include: • Reducing headcount by approximately 20%, resulting in a revised workforce of approximately 1,000 employees • Completing wind-down of all ongoing studies for GTX-102 for Angelman syndrome • Terminating UX701 for Wilson disease based on not achieving study goals • Reducing expenses across the company, including reduction of real estate footprint In addition to executing these critical expense reductions, the company is focused on driving successful launches for GENGLYCOS and FAYUVI and continuing to grow current product revenues.
    Read the source
  • SEC EDGAR · SEC filing · Nov 3, 2026

    On November 3, 2026, the Company announced a restructuring plan to reduce expenses (the “Restructuring”).
    Read the source

This reports what the source says. It says nothing about any individual's immigration status.